<DOC>
	<DOC>NCT01833663</DOC>
	<brief_summary>This study is a multi-site, randomized, opened and parallel-controlled clinical study. The patients up to the inclusion criteria are randomly treated with Solifenacin Succinate Tablets (5mg/d) or Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks. Before the dosing and at Week 4, 8 and 12 of the dosing, various examinations are made, and various indices are evaluated.</brief_summary>
	<brief_title>Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Urination Disorders</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Postmenopausal women aged ≤75. Signing of ICF. Willing to and able to correctly complete the urination diary. Complications of OAB for ≥12 weeks (including: urgent micturition, frequent urination (≥8 times in the daytime, and ≥2 times at the night) and/or urgent urinary incontinence). No dosing of other drugs of same kind within 14d. ≥8 urination times (24h) in the 1d urination diary. Clinicallysignificant dysuria(at the investigators' viewpoints). Serious stress urinary incontinence or mixed stress/urgent urinary incontinence (mainly stress one) confirmed by the investigators. At the ongoing intubatton or the intermittent selfintubatton. Evidencebased urinary tract infection or chronic inflammation in the recent 2 weeks (e.g. interstitial cystitis), bladder calculus, past pelvic radiotherapy, and past or existing pelvic malignant tumors. Uncontrolled narrowangle glaucoma, urinary/gastric retention, intestinal obstruction and other medical symptoms forbidden for anticholinergic drugs at the investigators' viewpoints. Nonpharmacotherapy (including electrotherapy) or bladder training within 2 weeks before the study initiation (or during the study). Dosing of diuretics and drugs with the cholinergic or anticholinergic adverse reactions Known or suspicious allergy to Solifenacin Succinate, other anticholinergic drugs or lactose. Clinicallysignificant symptoms inapplicable for clinical study at the investigators' viewpoints. Participation in other clinical studies within 30d before the random grouping. No completion of urination diary according to relevant instructions. Potentially clinically significant abnormalities (PCSA) inapplicable for clinical study at the investigators' viewpoints.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>Solifenacin Succinate Tablets</keyword>
	<keyword>Estrogen</keyword>
</DOC>